





Salud ósea en la adolescencia

**9° Congreso Argentino de Salud Integral del Adolescente
Sociedad Argentina de Pediatría
Buenos Aires, Agosto 2016**



Dra. Gisela Viterbo






Esqueleto 100 g
Calcio 30 g
Fósforo 15 g

Esqueleto 3000 g
Calcio 1200 g
Fósforo 600 g

Factores cuantitativos:

Masa Ósea { Densidad mineral ósea (DMO)
Contenido mineral óseo (CMO)



Dual Energy X Ray absorptiometry (DXA)



Región	DMO ¹ (g/cm ²)	Ajust. a edad ^{2, 3} (%)	Ajust. a edad ^{2, 3} Puntuación Z
L1	1,110	98	-0,2
L2	1,187	99	-0,1
L3	1,203	100	0,0
L4	1,204	100	0,0
L1-L2	1,150	100	0,0
L1-L3	1,169	100	0,0
L1-L4	1,179	100	0,0
L2-L3	1,195	100	0,0
L2-L4	1,198	100	0,0
L3-L4	1,204	100	0,0


Factores cualitativos:


- Propiedad de los materiales
 - Colágeno
 - Mineralización
- Microarquitectura
- Macroarquitectura




Pico de masa ósea (PMO)

Máxima cantidad de tejido óseo que se adquiere en el esqueleto al finalizar el crecimiento






DMO según edad y sexo



A los 18 años mujeres y varones adquirieron el 90% de la MO adulta

Las mujeres no ganan MO luego de 2.5 años postmenarca

Determinantes del PMO



- 1) **Prevención Primaria**: optimizar salud ósea en adolescentes sanos
- 2) **Prevención Secundaria**: identificar grupos en riesgo
- 3) **Prevención Terciaria**: mejorar la MO en poblaciones de riesgo

Determinantes del PMO

Lifestyle Factor	Grade
<i>Macronutrients</i>	
Fat	D
Protein	C
<i>Micronutrients</i>	
Calcium	A
Vitamin D	B
Micronutrients other than calcium and vitamin D	D
<i>Food Patterns</i>	
Dairy	B
Fiber	C
Fruits and vegetables	C
Detriment of cola and caffeinated beverages	C
<i>Adolescent Special Issues</i>	
Detriment of oral contraceptives	D
Detriment of DMPA injections	B
Detriment of alcohol	D
Detriment of smoking	C
<i>Physical Activity and Exercise</i>	
Effect on bone mass and density	A

Sistema de grados de evidencia

A	•Fuerte
B	•Moderada
C	•Limitada
D	•Inadecuada

Calcio




n: 103 gemelas

8-13 años, premenárquicas

Duración: 24 meses (n: 48)

Ingesta calcio basal: 786 mg/día vs 772 mg/día

Intervención: calcio carbonato 1200 mg/día vs placebo



Calcio

Effect of calcium supplementation on height, weight, and bone measures and plasma osteocalcin concentrations¹

	Absolute change (outcome – baseline)		Percentage difference in change (calcium – placebo)	
	Calcium group (n = 80)	Placebo group (n = 80)	Unadjusted (P)	Adjusted ² (P)
			%	%
Height (cm)	5.1 ± 0.2	5.2 ± 0.2	-0.1 ± 0.2 (0.7)	-0.0 ± 0.0 (0.9)
Weight (kg)	2.2 ± 0.2	1.9 ± 0.2	0.8 ± 0.8 (0.3)	0.8 ± 0.8 (0.3)
<u>Midshaft radius</u>				
BMC (g/cm)	0.041 ± 0.005	0.033 ± 0.005	2.1 ± 1.6 (0.2)	3.0 ± 1.4 (0.03)
Size-adjusted BMC ³				4.6 ± 0.9 (≤0.0001)
BW (cm)	0.012 ± 0.007	0.031 ± 0.006	-1.8 ± 0.9 (0.05)	-1.6 ± 0.9 (0.06)
BMD (g/cm ²)	0.037 ± 0.003	0.019 ± 0.003	3.9 ± 1.0 (0.0002)	4.5 ± 0.9 (≤0.0001)
<u>Distal radius</u>				
BMC (g/cm)	0.068 ± 0.011	0.035 ± 0.011	5.5 ± 3.4 (0.1)	8.4 ± 3.2 (0.009)
Size-adjusted BMC ³				5.5 ± 2.7 (0.04)
BW (cm)	0.075 ± 0.017	0.049 ± 0.015	1.2 ± 1.2 (0.3)	2.0 ± 1.2 (0.09)
BMD (g/cm ²)	0.026 ± 0.005	0.014 ± 0.005	4.8 ± 3.0 (0.1)	7.0 ± 2.7 (0.01)

n: 160; 80 ♂/80♀; 8.3-11.9 años

12 meses, doble ciego, randomizado

Ingesta calcio basal: 342 mg/día

Intervención: calcio carbonato 1000mg/día vs placebo

Calcio

Age	Calcium
RDA (mg/d) (Intake That Meets Needs of $\geq 97.5\%$ of Population)	
Infants	
0–6 mo	200 ^b
6–12 mo	260 ^b
1–3 y	700
4–8 y	1000
9–13 y	1300
14–18 y	1300



Actividad física

36 estudios randomizados,
controlados y 20
observacionales

30/36 muestran beneficios
estadísticamente
significativos entre el grupo
control y ejercicio



Actividad física

n: 154; 72♂, 82♀

15 años seguimiento

Inicio: 8-15 años, hasta 23-30 años

	Inactive n = 18	Average n = 36	Active n = 18
Chronological age (year)	14.1 (1.2)	14.3 (0.9)	14.6 (0.8)
Age at PHV	13.3 (1.2)	13.4 (0.9)	13.6 (0.8)
Maturity age (year from PHV)	0.9 (0.8)	0.9 (0.4)	1.0 (0.2)
Height (cm)	169.3 (8.5)	172.5 (5.8)	171.2 (6.5)
Weight (kg)	56.4 (8.9)	60.6 (9.0)	59.7 (9.2)
Total body lean mass (kg)	43.9 (6.0)	47.2 (5.3)	47.9 (6.2)
Total body fat mass (kg)	9.5 (5.7)	10.3 (6.4)	8.6 (4.4)
Calcium intake (mg/day)	1107 (481)	1347 (765)	1465 (681)
Physical activity (score)	2.1 (0.4)	3.0 (0.3)	3.7 (0.3)*





	Inactive n = 20	Average n = 42	Active n = 20
Chronological age (year)	12.4 (1.3)	12.8 (0.8)	12.8 (0.8)
Age at PHV	11.6 (1.2)	11.9 (0.8)	11.8 (0.7)
Maturity age (year from PHV)	0.9 (0.3)	0.9 (0.4)	0.9 (0.3)
Height (cm)	156.6 (9.9)	160.2 (5.8)	161.3 (8.1)
Weight (kg)	46.0 (11.6)	51.4 (9.9)	49.9 (10.9)
Total body lean mass (kg)	31.0 (5.2)	34.3 (4.7)	35.1 (6.4)*
Total body fat mass (kg)	13.2 (6.8)	14.4 (6.9)	12.3 (5.3)
Calcium intake (mg/day)	926 (377)	1117 (443)	885 (334)
Physical activity (score)	2.0 (0.4)	2.8 (0.3)	3.6 (0.6)*

Actividad física


	Inactive (n= 18)	Average (n= 36)	Active (n= 18)
Chronological age (year)	23.1 (2.2)	24.3 (2.0)	25.0 (2.5)*
Maturity age (year from PHV)	9.8 (2.6)	10.9 (1.9)	11.4 (2.4)
Height (cm)	177.8 (6.6)	180.5 (7.5)	178.5 (6.5)
Weight (kg)	79.6 (12.9)	84.7 (12.0)	83.6 (13.8)
Total body lean mass (kg)	57.8 (7.2)	61.1 (8.6)	61.9 (8.6)
Total body fat mass (kg)	17.6 (8.4)	19.2 (9.1)	17.1 (7.6)
Calcium intake (mg/day)	1390 (516)	1381 (673)	1412 (856)
Physical activity (score)	1.9 (0.5)	2.3 (0.6)	2.7 (0.5)*
Smokers (%)	22.2%	30.6%	11.1%
Alcohol consumption	3.5 (0.9)	3.3 (1.0)	3.5 (1.0)

	Inactive (n=20)	Average (n=42)	Active (n=20)
Chronological age (year)	22.7 (2.2)	23.5 (2.23)	22.6 (3.3)
Maturity age (year from PHV)	11.1 (2.4)	11.7 (2.2)	10.8 (2.1)
Height (cm)	164.2 (6.0)	167.1 (6.1)	168.3 (7.3)
Weight (kg)	65.3 (14.5)	69.7 (17.8)	68.9 (13.1)
Total body lean mass (kg)	38.1 (5.4)	40.5 (5.8)	41.5 (6.4)
Total body fat mass (kg)	23.8 (9.6)	25.4 (13.5)	23.7 (8.9)
Calcium intake (mg/day)	857 (408)	959 (447)	881 (345)
Physical activity (score)	1.8 (0.7)	2.1 (0.6)	2.5 (0.7)*
Smokers (%)	20.0%	40.5%	30.0%
Alcohol consumption ^a	3.9 (0.9)	3.9 (0.9)	3.6 (0.9)
Oral contraception (%)	70.0%	66.7%	60.0%
Oral contraception (years)	2.7 (1.5)	5.1 (3.3)	5.3 (2.9)*
Children 1 or more (%)	20.0%	26.2%	5.0%

Actividad física




Fracturas por stress



- Restricción a exposición solar
- Pigmentación de la piel
- Latitud ($>33^\circ$)
- Polución ambiental
- Protector solar ($>$ Factor8)

Otros factores:

- Obesidad
- Drogas (GC, AC, antirretrovirales)



Vitamina D

Age	Vitamin D
RDA (IU/d) (Intake That Meets Needs of $\geq 97.5\%$ of Population)	
Infants	
0–6 mo	400 ^b
6–12 mo	400 ^b
1–3 y	600
4–8 y	600
9–13 y	600
14–18 y	600



Lácteos

Food	Calcium Content (mg)
Dairy foods	
Milk	
Whole milk	276
Reduced fat milk (2%)	293
Low-fat milk (1%)	305
Skim milk (nonfat)	299
Reduced-fat chocolate milk (2%)	275
Low-fat chocolate milk (1%)	290
Yogurt	
Plain yogurt, low-fat	415
Fruit yogurt, low-fat	345
Plain yogurt, nonfat	452
Cheese	
Romano cheese	452
Swiss cheese	336
Pasteurized processed American cheese	323
Mozzarella cheese, part skim	311
Cheddar cheese	307
Muenster cheese	305
Nondairy foods	
Salmon	32
Sardines, canned	325
White beans, cooked	191
Broccoli, cooked	72
Broccoli, raw	42
Collards, cooked	226
Spinach, cooked	249
Spinach, raw	30
Baked beans, canned	120
Tomatoes, canned	84



2) Prevención secundaria

Genetic conditions

- Osteogenesis imperfecta
- Idiopathic juvenile osteoporosis
- Turner syndrome

Chronic illness

- Cystic fibrosis
- Connective tissue disorders (lupus, juvenile idiopathic arthritis, juvenile dermatomyositis)
- Inflammatory bowel disease, celiac disease
- Chronic renal failure
- Childhood cancer
- Cerebral palsy
- Chronic immobilization

Eating disorders, including anorexia nervosa, bulimia nervosa, eating disorders not otherwise specified, and the female athlete triad

Endocrine conditions

- Cushing syndrome
- Hypogonadism
- Hyperthyroidism
- Hyperparathyroidism
- Growth hormone deficiency
- Diabetes mellitus


Medications

- Glucocorticoids
- Anticonvulsants
- Chemotherapy
- Leuprolide acetate
- Proton pump inhibitors
- Selective serotonin reuptake inhibitors
- DMPA

3) Prevención terciaria

Tratamiento adecuado de la enfermedad de base

Suplementar con: -**calcio** a pacientes con GC o bajo dietas que impiden cumplir requerimientos diarios
-**vitamina D** a los no mantienen niveles normales




Conclusiones

La adolescencia es un período crítico para optimizar la adquisición del PMO

Los beneficios de la adecuada ingesta de calcio y la actividad física cuentan con la mejor evidencia científica disponible en la actualidad


Los beneficios de la ingesta de lácteos y de vitamina D, también cuentan con adecuada evidencia científica



Conclusiones

Los efectos de otros macro y micronutrientes sobre la salud ósea cuentan con un grado de evidencia científica limitado

Es importante analizar qué otros factores y estilos de vida se asocian al desarrollo de un mayor PMO y fortaleza ósea



Hospital de Pediatría
Garrahan